Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

alexandrossfakianakis shared this article with you from Inoreader Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with <i>FLT3</i> mutated AML Via Blood Cancer Journal - Issue - nature.com science feeds Blood Cancer Journal, Published online: 02 May 2022; doi:10.1038/s41408-022-00670-0 Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.